UNSPSC 51351635: Estradiol/trimegestone

Estradiol/trimegestone is a combination producto of hormonal steroids 17-? estradiol and trimegestone for the treatment of menopausal syndrome and in the prevention of postmenopausal osteoporosis.

UNSPSC 51351635 Estradiol/trimegestone is a Commodity code that identifies a single pharmaceutical product — a combined oral contraceptive containing estradiol and trimegestone. State and local governments procure this medication primarily through public health departments, county health systems, family planning clinics, and correctional facilities to serve uninsured and underinsured populations under Title X funding, Medicaid programs, and general public health missions. The code sees procurement activity concentrated among county health departments and municipal health agencies that operate community clinics, though the recent opportunities block contains no solicitations specifically requesting estradiol/trimegestone by name or NDC. One representative opportunity—the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) RFP S1070000015802 for generic multi-source pharmaceuticals and OTC products, posted January 20, 2026, with proposals due March 26, 2026—encompasses this product class within a broader pharmaceutical-supply contract serving state and local health facilities across Minnesota and Oregon. Vendors responding to MMCAP must supply products through three authorized wholesalers (AmerisourceBergen, Cardinal Health, and Morris & Dickson), maintain current Good Manufacturing Practices and Drug Supply Chain Security Act compliance, and submit pricing in fixed, net, or WAC-minus formats; evaluation weights 75 percent on price competitiveness and 25 percent on administrative compliance and EDI capability.

The absence of direct estradiol/trimegestone solicitations in the recent-opportunities block signals limited standalone procurement activity under this code at the state and local level. Most pharmaceutical procurement occurs through cooperative vehicles like MMCAP, state Medicaid managed-care contracts, or health system GPOs rather than individual RFPs. Geographic activity, where present, concentrates in states with active multistate cooperative purchasing programs and robust public health infrastructure (Minnesota, Florida, Texas, Colorado, and the Pacific Northwest). Vendors pursuing this code should monitor cooperative purchasing consortia and state health department solicitations rather than expect frequent direct RFPs. Integration with wholesaler chargeback systems, FDA compliance certification, and ability to meet volume commitments across multiple authorized distributors are standard qualifications. Pricing pressure remains intense—MMCAP weights price at 75 percent—and margins typically reflect generic-drug commoditization. This code represents a mature, low-pursuit-value segment for most vendors unless they hold existing wholesaler relationships or serve large health systems with negotiating leverage.